A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Study sponsor: Jazz Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-12-31Estimated
Enrollment · participants200Estimated
Source updated2026-11-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.